Table 9 The correlation between the expression level of the studied genes and clinicopathological features of hepatocellular carcinoma cases
Reduced expression | Over expression | |||||
|---|---|---|---|---|---|---|
Variable | ISGF3G | TNF-α | VISA* | CDK-7 | NOTCH4 | BAX |
Total: 17 (%) | 13 (76) | 15 (88) | 14 (82) | 12 (70) | 11 (64) | 13 (76) |
Age (Mean ± SD) (57 ± 10.2) |  |  |  |  |  |  |
< 57 = 10(59) | 8(80) | 9(90) | 8(80) | 7(70) | 7 (70) | 8(80) |
> 57 = 7(41) | 5(71) | 6(85) | 6(85) | 5(71) | 4 (57) | 5(71) |
Gender | Â | Â | Â | Â | Â | Â |
Male:13(76) | 10(77) | 12(92) | 11(85) | 10(77) | 9(69) | 11(85) |
Female:4(24) | 3(75) | 3(75) | 3(75) | 2(50) | 2(50) | 2(50) |
Tumor site | Â | Â | Â | Â | Â | Â |
Rirht = 11(65) | 9(82) | 10(90) | 8(73) | 7(64) | 6(55) | 9(82) |
Left = 6(35) | 4(66) | 5(83) | 6(100) | 5(83) | 5(83) | 4(66) |
Tumor size | Â | Â | Â | Â | Â | Â |
≤ 8 = 12(70) | 10(83) | 10(83) | 11(91) | 9(75) | 8(66) | 9 (75) |
> 8 = 5(30) | 3(60) | 5(100) | 3(60) | 3(60) | 5(100) | 4 (80) |
Grade | Â | Â | Â | Â | Â | Â |
I+II = 14(82) | 10(71) | 13(93) | 12(85) | 10(71) | 8(57) | 10(71) |
III = 3(18) | 3(100) | 2(66) | 2(66) | 2(66) | 3(100) | 3(100) |
Safety margin | Â | Â | Â | Â | Â | Â |
Pos 4 (24) | 2(50) | 3(75) | 4(100) | 3(75) | 3(75) | 3(75) |
Neg 13(76) | 11(85) | 12(92) | 10(77) | 9(69) | 8(61) | 10(77) |
Invasion | Â | Â | Â | Â | Â | Â |
Pos 9 (53) | 7(77) | 8(88) | 8(88) | 8(88) | 9(100) | 6(66) |
Neg 8(47) | 6(75) | 7(87) | 6(75) | 4(50) | 2(25) | 7(87) |
Cirrhosis | Â | Â | Â | Â | Â | Â |
Present: 10(59) | 8(80) | 9(90) | 8(80) | 7(70) | 7(70) | 9(90) |
Absent: 7(41) | 5(71) | 6(85) | 6(85) | 5(71) | 4(57) | 4(57) |
CAH | Â | Â | Â | Â | Â | Â |
Pos: 9 (53) | 7(77) | 8(88) | 7(77) | 6(66) | 6(66) | 8(88) |
Neg: 8(47) | 6(75) | 7(87) | 7(87) | 6(75) | 5(63) | 5(63) |